Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 mars 2023 17h36 HE | Source: MacroGenics, Inc.

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
17 nov. 2022 18h10 HE | Source: MacroGenics, Inc.

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
04 juin 2021 19h15 HE | Source: The Rosen Law Firm PA

PRVB BREAKING ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – PRVB

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2,...